Document Detail


Metabolic agents in the management of diabetic coronary patients: a new era.
MedLine Citation:
PMID:  17561287     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Modulation of myocardial free fatty acid metabolism is the key target for metabolic interventions in patients with coronary artery disease (CAD) with diabetes mellitus (DM). Because of its beneficial effects on heart metabolism at rest and on myocardial ischemia and left ventricular function, trimetazidine should be always combined with classical anti-ischemic treatment in patients with DM with CAD. We believe that, the new metabolic agents including L-carnitine, dichloroacetate, perhexiline and etomoxir will be added into our arsenal for the battle against CAD especially in patients with DM in the near future.
Authors:
Turgay Celik; Hurkan Kursaklioglu; Atila Iyisoy; Bekim Jata
Related Documents :
19301687 - Association of total cholesterol/ high-density lipoprotein cholesterol ratio with proxi...
9894617 - Role of secondary prevention in congestive heart failure due to coronary artery disease.
14579917 - Magnetocardiography in coronary artery disease with a new system in an unshielded setting.
11527817 - Seroprevalence of antibodies to microorganisms known to cause arterial and myocardial d...
16521647 - Heart failure: a unique presentation of typical atrioventricular nodal reentrant tachyc...
21130507 - Reconstitution of coronary vasculature in ischemic hearts by plant-derived angiogenic c...
Publication Detail:
Type:  Comment; Letter     Date:  2007-06-11
Journal Detail:
Title:  International journal of cardiology     Volume:  127     ISSN:  1874-1754     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-05-27     Completed Date:  2008-07-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  133-4     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carnitine / therapeutic use
Coronary Disease / complications,  drug therapy*,  physiopathology
Diabetes Mellitus / drug therapy*,  metabolism,  physiopathology
Diabetic Angiopathies / complications*
Dichloroacetate / therapeutic use
Enzyme Inhibitors / therapeutic use
Epoxy Compounds / therapeutic use
Humans
Perhexiline / therapeutic use
Trimetazidine / therapeutic use
Vasodilator Agents / therapeutic use
Vitamin B Complex / therapeutic use
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Epoxy Compounds; 0/Vasodilator Agents; 12001-76-2/Vitamin B Complex; 13425-80-4/Dichloroacetate; 5011-34-7/Trimetazidine; 541-15-1/Carnitine; 6621-47-2/Perhexiline; 82258-36-4/etomoxir
Comments/Corrections
Comment On:
Int J Cardiol. 2008 Jun 23;127(1):124-5   [PMID:  18199501 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Central sleep apnea is associated with blunted baroreflex sensitivity in patients with myocardial in...
Next Document:  Right coronary artery (RCA) aneurysm as a collateral circulation in sub totally occluded mid RCA ste...